Insulet Corporation (PODD) fair value analysis

S&P 500 & Nasdaq · Updated 2026-09-07

Insulet Corporation manufactures and markets the Omnipod insulin delivery system, a tubeless, wearable insulin pump designed for people with diabetes. The company operates globally, with a significant presence in the United States and Europe, serving patients who require insulin therapy management.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, PODD is trading at more than a 25% discount to estimated fair value.

PODD currently ranks #4 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $147.48
Sector: Healthcare
12-month range: $148.13–$318.77

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Moderate
Margin trend: Expanding
Revenue growth: High
RSI zone: Neutral
50/200-day trend: Downtrend
52-week position: The bottom quarter of its range
DCF cross-check: Overvalued

What our data shows for PODD

Our model validated 11 trailing price-to-earnings windows for PODD, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $148.13–$318.77.
The 14-day relative strength index sits at a neutral 62.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for PODD
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent PODD news

TickrTrends' derived news-sentiment signal for PODD is currently leaning positive, computed from recent coverage.

Insulet Corporation: Strong Growth Meets A New Execution Problem (NASDAQ:PODD) (seekingalpha.com, 2026-08-29)
TickrTrends take: Insulet Corporation faces a critical inflection point where operational challenges could test whether its current undervalued status remains justified. Investors monitoring PODD's valuation should track how management addresses execution issues, as healthcare companies trading at discount valuations often see those gaps close rapidly if operational performance deteriorates further or persist if problems are resolved. The tension between the company's growth trajectory and newly surfaced execution concerns will likely determine whether the undervaluation thesis holds or compresses through multiple contraction.
Is Wall Street Bullish or Bearish on Insulet Stock? (finance.yahoo.com, 2026-08-25)
TickrTrends take: Insulet Corporation operates in the Healthcare sector where TickrTrends' current analysis suggests PODD shares are undervalued based on derived valuation metrics. Market sentiment regarding Insulet from Wall Street analysts provides context for understanding whether the stock's current pricing reflects its fundamental value or represents an opportunity for valuation-focused investors. Tracking analyst positioning alongside valuation indicators can help investors assess whether PODD remains undervalued as market conditions and company fundamentals evolve.
Octane Medical Innovation Forum 2026 October 27-28 (manilatimes.net, 2026-08-17)
TickrTrends take: Poddium Inc (PODD) is scheduled to participate in the Octane Medical Innovation Forum 2026 on October 27-28, an event that provides visibility for healthcare companies within the investment community. Given TickrTrends' current assessment that PODD trades at an undervalued level, investor attention at such forums can serve as a catalyst for price discovery if the company effectively communicates its value proposition to analysts and fund managers. Valuation-focused readers should monitor whether this forum appearance leads to increased analyst coverage or institutional interest that could help narrow any valuation gap.

What people are saying

Follow the PODD conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is PODD stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), PODD is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is PODD's TickrTrends verdict?

PODD's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does PODD compare to other Healthcare stocks?

PODD ranks #4 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is PODD overbought or oversold?

PODD's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

PODD vs ADMA · PODD vs ALGN · PODD vs ASTH · PODD vs AZN · PODD vs BSX